Publications





Oncogenic RAS Regulates Long Noncoding RNA Orilnc1 in Human Cancer.
Cancer Res 2017 Jul 4;77(14):3745-3757. Epub 2017 May 4.
Center for Research on Reproduction & Women's Health, Department of Obstetrics and Gynecology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania.


PERK Is a Haploinsufficient Tumor Suppressor: Gene Dose Determines Tumor-Suppressive Versus Tumor Promoting Properties of PERK in Melanoma.
PLoS Genet 2016 Dec 15;12(12):e1006518. Epub 2016 Dec 15.
Department of Biochemistry and Molecular Biology, Hollings Cancer Center, Medical University of South Carolina, Charleston, South Carolina, United States of America.



Oncogenic BRAF-Mediated Melanoma Cell Invasion.
Cell Rep 2016 May 19;15(9):2012-24. Epub 2016 May 19.
Department of Biology, School of Arts and Sciences, University of Pennsylvania, Philadelphia, PA 19104, USA. Electronic address:

MAPK Activation Predicts Poor Outcome and the MEK Inhibitor, Selumetinib, Reverses Antiestrogen Resistance in ER-Positive High-Grade Serous Ovarian Cancer.
Clin Cancer Res 2016 Feb 19;22(4):935-47. Epub 2015 Oct 19.
Department of Obstetrics and Gynecology, University of Miami Miller School of Medicine, Miami, Florida. Department of Obstetrics and Gynecology, University of Pennsylvania, Philadelphia, Pennsylvania.

miR-200c/Bmi1 axis and epithelial-mesenchymal transition contribute to acquired resistance to BRAF inhibitor treatment.
Pigment Cell Melanoma Res 2015 Jul 16;28(4):431-41. Epub 2015 May 16.
Department of Pathology and Laboratory Medicine, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA.






OF